Sandbox:Roukoz: Difference between revisions

Jump to navigation Jump to search
Line 27: Line 27:
It is the classic type of inherited protein S deficiency. Typical findings include total protein S of approximately 50 percent of normal and free protein S as low as 15 percent of normal [15,19]. Most of the mutations responsible for type I deficiency are missense or nonsense mutations [31]. Microinsertions, microdeletions, and splice site mutations have also been reported.
It is the classic type of inherited protein S deficiency. Typical findings include total protein S of approximately 50 percent of normal and free protein S as low as 15 percent of normal [15,19]. Most of the mutations responsible for type I deficiency are missense or nonsense mutations [31]. Microinsertions, microdeletions, and splice site mutations have also been reported.


●Type II – Type II deficiency (normal total and free protein S; reduced protein S function) is rare (case reports only). This is also referred to as a qualitative defect. Five mutations described in the original reports were missense mutations located in the aminoterminal end of the protein, which includes the domains that interact with activated protein C [32-35]. These mutations may alter the conformation of protein S or interfere with carboxylation of the gamma-carboxyglutamic acid domain of the protein [33]. In a series of 118 French patients with thromboembolism associated with protein S deficiency, 26 had a serine to proline substitution at amino acid 460 (the Heerlen polymorphism), which affects protein S metabolism [36,37]. The low free plasma protein S may result from increased binding of the abnormal protein S to C4b-binding protein [38,39]. The thrombophilic risk with this polymorphism has been questioned [37].
*'''Type II:''' Normal total and free protein S, reduced protein S function
This type is rare (case reports only). This is also referred to as a qualitative defect. Five mutations described in the original reports were missense mutations located in the aminoterminal end of the protein, which includes the domains that interact with activated protein C [32-35]. These mutations may alter the conformation of protein S or interfere with carboxylation of the gamma-carboxyglutamic acid domain of the protein [33]. In a series of 118 French patients with thromboembolism associated with protein S deficiency, 26 had a serine to proline substitution at amino acid 460 (the Heerlen polymorphism), which affects protein S metabolism [36,37]. The low free plasma protein S may result from increased binding of the abnormal protein S to C4b-binding protein [38,39]. The thrombophilic risk with this polymorphism has been questioned [37].


●Type III – Type III deficiency (selectively reduced free protein S and protein S function; normal total protein S) is another type of quantitative defect.
*'''Type III:''' Selectively reduced free protein S and protein S function, normal total protein S
It is another type of quantitative defect


==Pathophysiology==
==Pathophysiology==

Revision as of 19:30, 13 September 2018


Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Roukoz A. Karam, M.D.[2]

Overview

Protein S deficiency is an autosomal dominant thrombophilia, which leads to an increased risk of thromboembolic events. Protein S is a vitamin K-dependent glycoprotein and plays a role in anticoagulation. It is mainly a cofactor to the activated protein C (APC), which inactivates coagulation factors Va and VIIa and thereby controlling the coagulation cascade.

Historical Perspective

Protein S was first discovered and purified in Seattle, Washington in 1979, and it was arbitrarily named protein S after the city it was discovered in. The function of this protein was still unknown; however, it was hypothesized that protein S plays a role in activating protein C. Protein S deficiency was first discovered in 1984 when two related individuals with recurrent thromboembolic events and normal coagulation tests were studied. At the time, protein C deficiency was usually associated with recurrent familial thrombosis. These individuals were found to have diminished anticoagulation activity with normal coagulation tests (including a normal protein C level), and when purified human protein S was added to their plasma, effective anticoagulation was restored. (1)

[Disease name] was first discovered by [name of scientist], a [nationality + occupation], in [year]/during/following [event].

The association between [important risk factor/cause] and [disease name] was made in/during [year/event].

In [year], [scientist] was the first to discover the association between [risk factor] and the development of [disease name].

In [year], [gene] mutations were first implicated in the pathogenesis of [disease name].

There have been several outbreaks of [disease name], including -----.

In [year], [diagnostic test/therapy] was developed by [scientist] to treat/diagnose [disease name].

Classification

Protein S deficiency can be subdivided into three types depending on whether the abnormality affects total protein S level, free protein S level, and/or protein S function:

  • Type I: Reduced total protein S, free protein S, and protein S function

It is the classic type of inherited protein S deficiency. Typical findings include total protein S of approximately 50 percent of normal and free protein S as low as 15 percent of normal [15,19]. Most of the mutations responsible for type I deficiency are missense or nonsense mutations [31]. Microinsertions, microdeletions, and splice site mutations have also been reported.

  • Type II: Normal total and free protein S, reduced protein S function

This type is rare (case reports only). This is also referred to as a qualitative defect. Five mutations described in the original reports were missense mutations located in the aminoterminal end of the protein, which includes the domains that interact with activated protein C [32-35]. These mutations may alter the conformation of protein S or interfere with carboxylation of the gamma-carboxyglutamic acid domain of the protein [33]. In a series of 118 French patients with thromboembolism associated with protein S deficiency, 26 had a serine to proline substitution at amino acid 460 (the Heerlen polymorphism), which affects protein S metabolism [36,37]. The low free plasma protein S may result from increased binding of the abnormal protein S to C4b-binding protein [38,39]. The thrombophilic risk with this polymorphism has been questioned [37].

  • Type III: Selectively reduced free protein S and protein S function, normal total protein S

It is another type of quantitative defect

Pathophysiology

Clinical Features

Differentiating [disease name] from other Diseases

Epidemiology and Demographics

Age

Gender

Race

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

Symptoms

Physical Examination

Laboratory Findings

Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Prevention

References